Achievement of endoscopic remission after induction reduces hospitalization burden in Crohn’s Disease: findings from a pooled post hoc analysis of risankizumab and upadacitinib Phase III trials
J Crohns Colitis. 2025 Feb 4;19(2):jjae128. doi: 10.1093/ecco-jcc/jjae128.
Panaccione et al. investigated the association between achievement of endoscopic remission following induction therapy and hospitalisation outcomes in Crohn’s disease. Patients achieving endoscopic remission at Week 12 experienced a 55% reduction in Crohn’s disease-related hospitalisation rates over the 52-week maintenance period. The results support endoscopic remission as an early therapeutic target.
This pooled post hoc analysis included 869 adult patients with moderate-to-severe Crohn’s disease from the Phase III FORTIFY and U-ENDURE trials. Participants who achieved clinical response to risankizumab or upadacitinib induction were included. Endoscopic remission was defined by SES-CD criteria, and hospitalisation outcomes were assessed over 52 weeks of maintenance therapy.
Keywords:
